BioNTech reiterates presence in Africa; WuXi eyes first Chinese vaccine plant; Chinese drugmaker blocks FDA checks
Welcome to Endpoints’ manufacturing news briefs, where we bring you essential news on new builds, collaborations, recalls, and more.
This week, we look into WuXi Biologics’ first vaccine manufacturing facility in China, as well as BioNTech’s reiteration of its continued work in Africa.
We also zero in on the latest government action, which sees CSL Seqirus land a four-year deal with the UK government to supply emergency vaccines, and Saudi Arabian plans for a new $133 million vaccine manufacturing facility.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.